Kallikrein 7 (KLK7) (NM_005046) Human Recombinant Protein
CAT#: TP720313M
Recombinant protein of human kallikrein-related peptidase 7 (KLK7), transcript variant 1
Need it in bulk or customized? Get a free quote |
CNY 7,220.00
货期*
2周
规格
经常一起买 (1)
Specifications
Product Data | |
Species | Human |
Expression Host | HEK293 |
Expression cDNA Clone or AA Sequence |
Glu23-His252
|
Tag | C-His |
Predicted MW | 26.2 kDa |
Concentration | lot specific |
Purity | >95% as determined by SDS-PAGE and Coomassie blue staining |
Buffer | Supplied as a 0.2 um filtered solution of 20mM HEPES, 150mM NaCl, pH 7.5. |
Storage | Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles. |
Stability | Stable for at least 3 months from date of receipt under proper storage and handling conditions. |
Endotoxin | < 0.1 EU per µg protein as determined by LAL test |
Reference Data | |
RefSeq | NP_005037 |
Locus ID | 5650 |
UniProt ID | P49862, A0A024R4H6, B4DHX9 |
Cytogenetics | 19q13.41 |
Synonyms | hK7; PRSS6; SCCE |
Summary | This gene encodes a member of the kallikrein subfamily of serine proteases. These enzymes have diverse physiological functions and many kallikrein genes are biomarkers for cancer. The encoded protein has chymotrypsin-like activity and plays a role in the proteolysis of intercellular cohesive structures that precedes desquamation, the shedding of the outermost layer of the epidermis. The encoded protein may play a role in cancer invasion and metastasis, and increased expression of this gene is associated with unfavorable prognosis and progression of several types of cancer. Polymorphisms in this gene may play a role in the development of atopic dermatitis. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene, which is one of fifteen kallikrein subfamily members located in a gene cluster on chromosome 19. [provided by RefSeq, May 2011] |
Protein Families | Druggable Genome, Secreted Protein |
Documents
FAQs |
SDS |
其它Kallikrein 7产品
Customer
Reviews
Loading...